Fig. 3From: A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthmaChange in FEV1 over time. Baseline adjusted FEV1 over time for S1226 was significantly higher than placebo (P = 0.043). Error bars show the standard deviationBack to article page